Artificial intelligence (AI) is rapidly transforming cardiovascular medicine, particularly in the domain of coronary hemodynamics assessment and personalized treatment planning. This review synthesizes current scientific evidence regarding the integration of AI-based computational models for simulating coronary blood flow, evaluating lesion-specific ischemia, and guiding clinical decision-making in coronary artery disease (CAD). Emphasizing recent advances, the article explores the epidemiology of CAD, underlying pathophysiology, risk stratification, clinical presentation, diagnostic innovations, contemporary management strategies, and guideline-driven recommendations. Special attention is given to the mechanistic underpinnings, clinical utility, and future scope of AI-enabled tools in optimizing patient outcomes and advancing precision cardiology.
Coronary artery disease remains the leading cause of morbidity and mortality worldwide, imposing a significant burden on healthcare systems. Traditional approaches to diagnosis and management, although effective, are often limited by subjective interpretation, operator variability, and challenges in integrating complex patient data. The advent of artificial intelligence encompassing machine learning, deep learning, and advanced computational modeling has ushered in a paradigm shift, offering unprecedented opportunities for objective, reproducible, and patient-specific coronary hemodynamic simulations. This review aims to provide a comprehensive analysis of AI-driven technologies in coronary assessment, from disease characterization to treatment planning, and their integration into clinical practice.
Coronary artery disease accounts for over 9 million deaths annually, representing a global health crisis. The prevalence is particularly high in low- and middle-income countries, where risk factor control and access to advanced diagnostics are suboptimal. The socioeconomic impact is profound, with substantial direct and indirect costs related to hospitalizations, interventions, and lost productivity. Despite advancements in pharmacotherapy and revascularization, a significant proportion of patients experience recurrent events or residual ischemia, highlighting the need for precise and individualized treatment strategies. AI-based hemodynamic modeling has emerged as a critical adjunct in addressing these gaps by enhancing diagnostic accuracy and optimizing resource allocation.
The pathophysiology of CAD is multifactorial, involving a dynamic interplay between atherosclerotic plaque development, endothelial dysfunction, inflammatory processes, and microvascular impairment. Hemodynamic significance of coronary lesions depends not only on anatomical stenosis severity but also on complex physiological determinants such as coronary flow reserve, collateral circulation, and myocardial demand. Traditional angiography provides a limited two-dimensional perspective, failing to capture dynamic flow characteristics. AI-powered computational fluid dynamics (CFD) models leverage imaging data such as coronary CT angiography (CCTA) or invasive angiography to simulate blood flow, pressure gradients, and fractional flow reserve (FFR), facilitating a mechanistic understanding of lesion-specific ischemia.
Established risk factors for coronary artery disease include hypertension, dyslipidemia, diabetes mellitus, smoking, family history, and sedentary lifestyle. Emerging evidence also implicates novel biomarkers, genetic predisposition, and environmental exposures. AI algorithms are increasingly being trained on large, multimodal datasets to identify subtle patterns, predict individual risk trajectories, and enable proactive intervention. By integrating demographic, biochemical, imaging, and genomic data, AI-driven risk stratification tools can assist clinicians in tailoring preventive and therapeutic strategies.
Patients with CAD may present with a spectrum of clinical manifestations, ranging from asymptomatic subclinical disease to stable angina, acute coronary syndromes, heart failure, or sudden cardiac death. The clinical assessment requires careful synthesis of history, physical examination, electrocardiography, and non-invasive or invasive imaging. AI-based platforms can assist in automated detection and characterization of ischemic changes, stratifying patients by event risk, and supporting timely triage especially in acute or ambiguous presentations. Moreover, real-time AI analytics can enhance patient monitoring and early warning systems.
Accurate diagnosis of flow-limiting coronary lesions is pivotal for effective management. Conventional modalities include stress testing, CCTA, invasive coronary angiography, and FFR measurement. AI-enhanced interpretation of CCTA images enables non-invasive FFR computation (FFR-CT), providing lesion-specific physiological assessment with high diagnostic concordance to invasive FFR. Machine learning algorithms refine plaque characterization, quantify stenosis, and predict adverse outcomes by integrating anatomical and functional imaging data. These advances reduce the need for invasive procedures, lower costs, and improve patient comfort without compromising diagnostic accuracy.
Management of CAD encompasses medical therapy, percutaneous coronary intervention (PCI), and coronary artery bypass grafting (CABG). The selection of optimal strategy depends on ischemia burden, anatomical complexity, comorbidities, and patient preferences. AI-supported decision tools can synthesize clinical, imaging, and physiological data to recommend individualized therapy pathways. Hemodynamic simulations inform the appropriateness of revascularization, guide stent selection and positioning, and predict post-procedural flow dynamics. AI can also identify patients likely to benefit from advanced therapies or intensified risk factor modification, thereby improving outcomes and resource utilization.
Recent years have witnessed a surge in AI-driven technologies for coronary hemodynamic simulation and treatment planning. Notable advances include deep learning-based FFR-CT, AI-assisted virtual stenting, and integration of CFD models into clinical workflow. Large-scale, multicenter studies have validated the diagnostic and prognostic utility of these tools, demonstrating non-inferiority or superiority compared to traditional approaches. Emerging paradigms such as digital twins, explainable AI, and federated learning hold promise for further enhancing model transparency, generalizability, and clinical adoption. Collaboration between clinicians, engineers, and regulatory agencies is accelerating the translation of these innovations from research to bedside.
International cardiology guidelines increasingly recognize the role of non-invasive physiological assessment in CAD management. The European Society of Cardiology (ESC) and American College of Cardiology/American Heart Association (ACC/AHA) endorse the use of FFR-CT and AI-assisted imaging for intermediate lesions or ambiguous cases. These recommendations underscore the importance of integrating AI-based simulations into multidisciplinary decision-making, ensuring that therapy is guided by robust physiological evidence rather than anatomical assessment alone. Ongoing guideline revisions are likely to further incorporate AI-enabled diagnostics as evidence continues to accrue.
Artificial intelligence is revolutionizing the simulation and interpretation of coronary hemodynamics, offering clinicians powerful tools to enhance diagnostic precision, optimize treatment planning, and personalize care for patients with coronary artery disease. By bridging the gap between anatomical imaging and physiological assessment, AI-driven technologies are poised to improve patient outcomes, reduce unnecessary interventions, and streamline clinical workflows. Continued research, real-world validation, and thoughtful integration into practice guidelines will be essential to fully realize the transformative potential of AI in cardiovascular medicine.
1.
Rural colon cancer patients face higher risks, but minimally invasive surgery could narrow gap
2.
Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal
3.
Laryngeal Transplant Helped a Cancer Patient Speak Again in Pioneering Study
4.
The amount of liver tissue removed during gallbladder surgery has no discernible impact on overall survival.
5.
Long-Acting Interferon Therapy Approved for ET
1.
Molecular Network Mapping in Hematologic Disease
2.
Metabolic Reprogramming of the Tumor Microenvironment: Mechanisms, Clinical Relevance, and Emerging Therapeutic Strategies
3.
Hematopoietic Stem Cell Clonal Dynamics Across the Lifespan
4.
Connected Hematology Laboratory Networks for Automated Cross-Institution Data Exchange
5.
Digital Oncology Ecosystems Integrating Longitudinal Patient Trajectories: Transforming Cancer Care through Data-Driven Innovation
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
2.
Common side effects of cancer treatment and how they are managed
3.
Clinical Excellence in Hematology
4.
Best Practices in Hematology
5.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation